Acticor Biotech announced last night that it had decided to change the primary endpoint of its Phase 2/3 study to a single endpoint, namely the reduction in the number of patients dying or suffering severe disability as a result of stroke.

This change, which follows consultations with the European (EMA) and US (FDA) regulatory agencies, will enable the study size to be reduced to 400 patients, compared with 1000 previously, and thus enable clinical results to be obtained as early as mid-2024, rather than 2025.

In its press release, Acticor explains that the aim is to achieve registration of glenzocimab in Europe and the United States by 2028 at the latest.

To date, the study deployed in the United States, Europe, Israel and Great Britain has enrolled over 380 patients, 35% of whom have undergone mechanical thrombectomy.

After jumping more than 5% mid-morning, Acticor shares on the Paris Bourse were unchanged at lunchtime.

Copyright (c) 2023 CercleFinance.com. All rights reserved.